| Characteristic | R&D | Debt | M&A | Dividends | Share buybacks | Capex |
|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - |
| - | - | - | - | - | - | - |
| - | - | - | - | - | - | - |
| - | - | - | - | - | - | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Download
Sources
Release date
June 2025
Region
Europe, United States
Survey time period
2021 to 2024
Special properties
U.S. and European biopharma leaders
Supplementary notes
Figures may not total 100% due to rounding.
Citation formats









